comparemela.com

Latest Breaking News On - கில்‌ப்யாட்‌ரிக் டவுன்சென்ட் - Page 8 : comparemela.com

Two Bipartisan Bills Aim to Encourage Competition in the Biopharma Industry | Kilpatrick Townsend & Stockton LLP

To embed, copy and paste the code into your website or blog: Drug pricing and innovation are hot topics in Washington right now with several bills making their way through the legislative process, many in a bipartisan fashion. On April 23, 2021, two of these bills were signed into law by President Biden. The first bill, the Ensuring Innovation Act, limits new drug exclusivity, thereby making it easier for generics to enter the market and spur competition. The second bill, the Advancing Education on Biosimilars Act of 2021, is designed to increase the availability of information about biologics and biosimilars in an effort to educate healthcare providers and patients and indirectly increase competition. 

Insights into the States 2021 BD Examination, Enforcement Priorities | Kilpatrick Townsend & Stockton LLP

advisor or adviser in marketing materials, disclosures, customer agreements, websites, on business cards or on social media while operating in the capacity of a BD’s RR (not as an IA); 13 32 percent of BDs that allowed RRs to use the title had no prerequisite for the RRs’ use of that title ( e.g., requiring the RR to be dually registered as both an RR and IA representative). 14 38 percent of BDs surveyed did not have E&O insurance to cover investor losses. 15 16 2. Reg BI Survey, Phase Two & Examinations, 2021 The Committee plans to conduct Phase Two of the Reg BI Survey this summer, and also expects that the States will begin to conduct Reg BI examinations (both remotely, and onsite); those exams may include the Reg BI Survey or occur independent of the Reg BI Survey. It appears that originally, the Committee planned to gather the Phase Two survey results and then roll-out the Reg BI examination modules to the States – more on modules below – but as we all know by

Apple Opposes Chinese Electronics Company s Proposed AIFONX Trademark

Tech your username 4 hours ago On Tuesday, Apple Inc. opposed a trademark applied for by Shenzhen Guardian Bao Communication Co. Ltd. (Shenzhen Guardian). The Trademark Trial and Appeal Board (TTAB) filing takes issue with the proposed mark on the basis that it closely replicates Apple’s registered “iPhone” marks, including those used in connection with the iPhone X device Apple makes, markets, and sells. The similarity of the proposed “aifonx” mark to its own Apple contends, as reprinted below, is likely cause consumer confusion and harm its brand. According to the opposition, Apple’s mark has been famous since long prior to the filing date of Shenzhen Guardian’s application in July 2020. In addition, the opposer’s marks have been used in connection with the iPhone X since Nov. 3, 2017 when Apple brought the model to market.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.